Duloxetine
- Generic Name
- Duloxetine
- Brand Names
- Cymbalta, Drizalma, Irenka, Yentreve, Duloxetine Zentiva, Duloxetine Mylan, Duloxetine Lilly
- Drug Type
- Small Molecule
- Chemical Formula
- C18H19NOS
- CAS Number
- 116539-59-4
- Unique Ingredient Identifier
- O5TNM5N07U
- Background
Duloxetine is a dual serotonin and norepinephrine reuptake inhibitor. It was originally discovered in 1993 and developed by Eli Lilly and Company as LY248686. Duloxetine first received approval from the FDA in August, 2004 as Cymbalta for the treatment of Major Depressive Disorder. It has since received approval for a variety of indications including the treatment of neuropathic pain, Generalized Anxiety disorder, osteoarthritis, and stress incontinence. Duloxetine continues to be investigated for the treatment of pain in cancer, surgery, and more.
- Indication
Indicated for:
1) Management of Major Depressive Disorder.
2) Management of Generalized Anxiety Disorder.
3) Management of diabetic peripheral neuropathy.
4) Management of fibromyalgia.
5) Management of chronic musculoskeletal pain.
6) Management of osteoarthritis of the knee in adults.
7) Management of chronic lower back pain in adults.
8) Management of stress urinary incontinence in adult women.
Off-label uses include:
1) Management of chemotherapy-induced peripheral neuropathy.
2) Management of stress urinary incontinence in adult men after prostatectomy until recovery is complete.
- Associated Conditions
- Chronic Lower Back Pain (CLBP), Chronic Musculoskeletal Pain, Diabetic Peripheral Neuropathic Pain (DPN), Fibromyalgia, Generalized Anxiety Disorder, Major Depressive Disorder (MDD), Osteoarthritis of the Knee, Stress Urinary Incontinence (SUI)
- Associated Therapies
- -
Duloxetine for Treatment of Painful Temporomandibular Joint Disorder
- Conditions
- Interventions
- First Posted Date
- 2009-09-22
- Last Posted Date
- 2021-05-25
- Lead Sponsor
- University of Maryland, Baltimore
- Target Recruit Count
- 24
- Registration Number
- NCT00981149
- Locations
- 🇺🇸
University of Maryland Dental School, Baltimore, Maryland, United States
A Study for Adult Patients With Fibromyalgia
- Conditions
- Interventions
- First Posted Date
- 2009-08-25
- Last Posted Date
- 2011-11-03
- Lead Sponsor
- Eli Lilly and Company
- Target Recruit Count
- 308
- Registration Number
- NCT00965081
- Locations
- 🇲🇽
For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Morelia, Mexico
An Open Label Trial of Duloxetine in the Treatment of Irritable Bowel Syndrome and Comorbid Generalized Anxiety Disorder
- Conditions
- Interventions
- First Posted Date
- 2009-08-18
- Last Posted Date
- 2014-07-09
- Lead Sponsor
- West Penn Allegheny Health System
- Target Recruit Count
- 17
- Registration Number
- NCT00961298
Pilot Study of Duloxetine in Adult Attention Deficit Hyperactivity Disorder(ADHD)
- Conditions
- Interventions
- First Posted Date
- 2009-07-16
- Last Posted Date
- 2010-12-14
- Lead Sponsor
- Université de Montréal
- Target Recruit Count
- 40
- Registration Number
- NCT00940693
- Locations
- 🇨🇦
Centre Hospitalier Universitaire de Montréal: Hôpital Notre-Dame, Montreal, Quebec, Canada
Assessment of Cognitive Functioning Before and After Treatment With Duloxetine
- First Posted Date
- 2009-07-07
- Last Posted Date
- 2013-08-13
- Lead Sponsor
- University of Texas Southwestern Medical Center
- Target Recruit Count
- 30
- Registration Number
- NCT00933439
- Locations
- 🇺🇸
Mood Disorders Research Program and Clinic - UT Southwestern Medical Center, Dallas, Texas, United States
A Study to Evaluate the Pharmacokinetics of Duloxetine in Chinese Han Healthy Subjects
- First Posted Date
- 2009-07-07
- Last Posted Date
- 2010-06-15
- Lead Sponsor
- Shanghai Mental Health Center
- Target Recruit Count
- 36
- Registration Number
- NCT00933452
- Locations
- 🇨🇳
Shanghai Mental Health Center, Shanghai, Shanghai, China
Duloxetine Versus Pregabalin for Alcohol Dependence
- Conditions
- Interventions
- First Posted Date
- 2009-06-29
- Last Posted Date
- 2017-05-04
- Lead Sponsor
- The Scripps Research Institute
- Target Recruit Count
- 150
- Registration Number
- NCT00929344
- Locations
- 🇺🇸
The Scripps Research Institute Pearson Center for Alcoholism and Addiction Research, La Jolla, California, United States
Duloxetine for Major Depression in Peri-/Postmenopausal Women
- First Posted Date
- 2009-04-28
- Last Posted Date
- 2012-02-08
- Lead Sponsor
- Hamilton Health Sciences Corporation
- Target Recruit Count
- 70
- Registration Number
- NCT00889369
- Locations
- 🇨🇦
Women's Health Concerns Clinic, Hamilton, Ontario, Canada
Combination Pain Therapy in HIV Neuropathy
- Conditions
- Interventions
- First Posted Date
- 2009-03-17
- Last Posted Date
- 2021-11-04
- Target Recruit Count
- 15
- Registration Number
- NCT00863057
- Locations
- 🇺🇸
Houston AIDS Research Team CRS, Houston, Texas, United States
🇺🇸Ucsd, Avrc Crs, San Diego, California, United States
🇺🇸Harbor-UCLA Med. Ctr. CRS, Torrance, California, United States
A Study in the Treatment of Children and Adolescents With Major Depressive Disorder
- Conditions
- Interventions
- First Posted Date
- 2009-02-24
- Last Posted Date
- 2012-04-19
- Lead Sponsor
- Eli Lilly and Company
- Target Recruit Count
- 463
- Registration Number
- NCT00849693
- Locations
- 🇲🇽
For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Tlalnepantla, Mexico
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.